Curriculum Vitae

Andy Coop
Professor and Chair
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy
20 South Pine Street, Room N731, Baltimore, Maryland 21201

Phone 410-706-2029
Fax 410-706-5017
E-mail acoop@rx.umaryland.edu

Education

B.A., M.A.   St. Catherine's College, University of Oxford, Oxford, UK, 1987-1991. Thesis: The Chemistry of Organolead Compounds. (Supervisor: Dr. M. G. Moloney)

Ph.D. School of Chemistry, University of Bristol, Bristol, UK, 1991-1994.  Thesis: Ring Constrained Analogues of Buprenorphine. (Supervisor: Dr. J. W. Lewis).

Professional Experience

1995-1998 Fogarty Fellow: (Sponsor: Dr. K. C. Rice). Laboratory of Medicinal Chemistry, NIDDK, NIH, Bethesda, Maryland, USA.

1999-2003 Assistant Professor: Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

2003-2008 Associate Professor: Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

2008- Professor: Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

Administrative Positions

Chair, Department of Pharmaceutical Sciences (07- Present)
Vice Chair of Academic Affairs, Dept. Pharmaceutical Sciences (06-07)

Awards

  • Joseph Cochin Young Investigator Award, College on Problems of Drug Dependence, 2003.
  • Teacher of the Year, University of Maryland School of Pharmacy, 2001.
  • Fogarty Fellowship (National Institutes of Health); April, 1995 - December, 1998.
  • Second and Third Year Organic Chemistry Practical Prize, University of Oxford, UK, 1990.

Teaching Experience

  • Graduate
  • Professional (Medicinal Chemistry)

Membership on National Committees

  • Board of Directors, College on Problems of Drug Dependence (CPDD) (June 2010 - )
  • Publications Committee, American Association of Pharmaceutical Scientists (AAPS) (2008 - )
  • Biological Coordinator, Drug Evaluation Committee (DEC) of the College on Problems of Drug Dependence (CPDD). (2000-2007)
  • Electronic Communications Committee, College on Problems of Drug Dependence (CPDD). (2002-2005)
  • Membership Committee, College on Problems of Drug Dependence (CPDD) (2005-2007)

Consulting

  • Expert Witness for the US Department of Justice
  • Darby and Darby Professional Corporation
  • Heenan Blaikie LLP

Membership in Professional Societies

Journal Editorial Boards

Manuscript Reviewer

Funding

  1. Maryland Industrial Partnerships (MIPS). A Combination Test for the Detection of Illicit Drugs. 2/1/00 - 1/31/01. Principal Investigator.
     
  2. National Institute on Drug Abuse (NIDA).  (R01, DA 13583) Opioids with Delta Antagonist and Mu Agonist Activity. 2/1/01 - 1/31/13. Principal Investigator.
     
  3. National Institute on Drug Abuse (NIDA). (R01, DA 14986) GHB Abuse: Chemistry and Neurobiology. 9/26/01-7/31/04. Co-Investigator - PI: Dr. Charles France, University of Texas Health Science Center at San Antonio.
     
  4. National Institute on Drug Abuse (NIDA). (R01, DA 13978) Development of Novel Agents with Anti-Cocaine Properties. 9/30/01 - 1/31/11. Co-Investigator - PI: Dr. Rae Matsumoto, University of Oklahoma, University of Mississippi.and University of West Virginia.
     
  5. Unihart, Inc. Synthesis of Analogs of Xenaldial. 11/1/04-10/31/05. Principal Investigator.
     
  6. Neuronascent, Inc. The Synthesis of Novel Neurogenic Agents. 7/1/05-2/28/06. Principal Investigator.
     
  7. National Cancer Institute (NCI, R01 CA 107331). Restoration of Tumor Suppression Activity in Malignant Melanoma. 7/1/06-6/30/10. Co-Investigator - PI: Dr. David Weber, University of Maryland School of Medicine.
     
  8. Samuel Waxman Foundation.  Transcriptional Targeting in Translational Therapy. 7/1/06-6/30/08. Co-Investigator - PI: Dr. A. Melnick, Albert Einstein School of Medicine Yeshiva University.

Career Advancement Awards

  1. National Institute on Drug Abuse (NIDA). (K02, DA 19634). Reversing the Toxic Effects of Drugs of Abuse. 5/1/05-4/30/10. $527,695 (Total Costs). Principle Investigator.

Fellowships for Graduate Students

  1. Linn N. Thatcher: National Research Service Award (NRSA). National Institute on Drug Abuse (NIDA). (F31, DA 15586) Opioids with a Reduced Potential to Produce Tolerance. 7/1/02-6/30/04.
     
  2. Matthew M. Metcalf: Slama Departmental Fellowship. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy. 9/1/04-4/30/05.
     
  3. Matthew Metcalf: Ruth L. Kirschstein National Research Service Award (NRSA). National Institute on Drug Abuse (NIDA). (F31, DA 18025) Kappa Opioid Antagonists with a Shortened Duration of Action. 5/1/05-4/30/07.
     
  4. Trudy A. Smith: University of Maryland Baltimore, Enrichment Fellowship. 8/1/05-7/31/07.
     
  5. Christopher W. Cunningham: Ruth L. Kirschstein National Research Service Award (NRSA) (F31, DA 21049). National Institute on Drug Abuse (NIDA). Opioid Analgesics with Reduced Constipation. 8/1/06-7/31/09.
     
  6. Susan L. Mercer: Departmental Fellowship. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy. 9/1/07-8/31/08.

Bibliography

  1. J. W. Barton, A. Coop and J. W. Lewis: Diels-Alder Reactions of Thebaines with Cycloalkenones; LiBF4 as a Novel Diels-Alder Catalyst. Tetrahedron Lett., 1993, 34, 6777-6778.
     
  2. J. E. H. Buston, A. Coop, R. Keady, M. G. Moloney and R. M. Thompson: The Synthesis, Characterisation and Reactivity of some Lead (IV) Carboxylates. J. Chem. Res.(m), 1994,1101-1116. (J. Chem. Res.(s), 1994, 205)
     
  3. A. Coop, K. Grivas, S. Husbands, J. W. Lewis and J. Porter: Ring Constrained Analogues of the Thevinones; Diels-Alder Reactions of Thebaines with 1-Indenone and Methylene Cycloalkenones. Tetrahedron Lett., 1995, 36, 1689-1692.
     
  4. A. Coop, K. Grivas, S. Husbands and J. W. Lewis: Methylation of the Enolates of Thevinone and Some Analogues. Tetrahedron, 1995, 51, 9681-9698.
     
  5. L. Guo, A. Coop, J. W. Lewis and J. R. Traynor: Affinity and Efficacy Studies of Ring Constrained Analogues of Buprenorphine at mu-Opioid Receptors. Analgesia, 1995, 1, 450-452.
     
  6. A. Coop, J. W. Lewis and K. C. Rice: Direct and Simple Conversion of Thebaine to Oripavine. J. Org. Chem., 1996, 61, 6774.
     
  7. A. Coop, J. W. Janetka, J. W. Lewis and K. C. Rice: L-Selectride as a General Reagent for the O-Demethylation and N-Decarbomethoxylation of Opium Alkaloids and Derivatives. J. Org. Chem., 1998, 63, 4392-4396.
     
  8. A. Coop and K. C. Rice: L-Selectride as Convenient Reagent for the Selective Cleavage of Carbamates. Tetrahedron Lett., 1998, 39, 8933-8934.
     
  9. E. L. May, A. E. Jacobson, M. V. Mattson, A. Coop, M. D. Aceto, E. R. Bowman, J. R. Traynor, J. H. Woods and L. S. Harris: Synthesis, In Vitro, and In Vivo Activity of N-p-Substituted-Benzyl-(-)- and (+)-N-Normetazocines, (-)- and (+)-N-Nor-morphinans, N-Nor-ketobemidones, and (-)-N-Nor-4,5-epoxymor-phinans. Med. Chem. Res., 1998, 8, 311-321.
     
  10. A. Coop and K. C. Rice: A Novel Synthesis of Thebaine from Codeine. Heterocycles, 1998, 49, 43-47.
     
  11. A. Coop and K. C. Rice: Direct and Simple Conversion of Codeine to Thebainone-A and Dihydro-thebainone. Heterocycles, 1999, 50, 39-42.
     
  12. A. Coop and A. E. Jacobson: The LMC Delta Opioid Recognition Pharmacophore. Comparison of SNC80 and Oxymorphindole. Bioorg. Med. Chem. Lett., 1999, 9, 357-362.
     
  13. A. Coop, R. B. Rothman, C. Dersch, J. Partilla, F. Porreca, P. Davis, A. E. Jacobson and K. C. Rice: Delta Opioid Affinity and Selectivity of 4-Hydroxy-3-methoxyindolomorphinan Analogues Related to Naltrindole. J. Med. Chem., 1999, 42, 1673-1679.
     
  14. A. Coop and K. C. Rice: Studies into the Direct Oxidation of Codeinone to 14-Hydroxycodeinone. Tetrahedron, 1999, 55, 11429-11436.
     
  15. H. Yu, L. Wang, X. Tian, J. Flippen-Anderson, A. Coop and K. C. Rice: Synthesis of a Novel 7,14β-Ethano-Bridged Opiate. Heterocycles, 1999, 51, 2343-2347.
     
  16. J. R. Traynor, L. Guo, A. Coop, J. W. Lewis and J. H. Woods: Ring-Constrained Orvinols as Analogues of Buprenorphine: Differences in Opioid Activity Related to the Conformation of the C-20 Hydroxyl Group. J. Pharmacol Exp. Ther., 1999, 291, 1093-1099.
     
  17. S. W. Breeden, A. Coop, S. M. Husbands, and J. W. Lewis: 6-O-Demethylation of the Thevinols with Lithium Aluminium Hydride: Selective Demethylation of a Tertiary Alkyl Methyl Ether in the Presence of an Aryl Methyl Ether. Helv. Chim. Acta, 1999, 82, 1978-1980.
     
  18. X. Zhang, K. C. Rice, S. N. Calderon, H. Kayakiri, L. Smith, A. Coop, A. E. Jacobson, R. B. Rothman, P. Davis, K. Becketts, F. Porreca: Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis and Biological Evaluation of Diarylmethyl Piperazines and Diarylmethyl Piperidines as Novel, Nonpeptidic Delta Opioid Receptor Ligands. J. Med. Chem., 1999, 42, 5455-5463.
     
  19. A. Coop, J. Pinto, L. Wang, R. B. Rothman, C. Dersch, A. E. Jacobson and K. C. Rice: Delta Opioid Binding Selectivity of 3-Ether Analogs of Naltrindole. Bioorg. Med. Chem. Lett., 1999, 9, 3435-3438.
     
  20. D. Y. Maeda, W. Williams, W. D. Bowen, and A. Coop: A Sigma-1 Receptor Selective Analog of BD1008. A Potential Substitute for (+)-Opioids in Sigma Receptor Binding Assays. Bioorg. Med. Chem. Lett., 2000, 10, 17-18.
     
  21. A. Coop, I. Berzetei-Gurske, J. Burnside, L. Toll, J. R. Traynor, S. M. Husbands, and J. W. Lewis: Sructural Determinants of Opioid Activity in the Orvinols and Related Strcutures: Ethers of 7,8-Cyclopentano-analogs of Buprenorphine. Helv. Chim. Acta, 2000, 83, 687-693.
     
  22. A. Coop, C. L. Norton, I. Berzetei-Gurske, J. Burnside, L. Toll, S. M. Husbands, and J. W. Lewis: Sructural Determinants of Opioid Activity in the Orvinols and Related Strcutures: Ethers of Orvinol and Iso-orvinol. J. Med. Chem., 2000, 43, 1852-1857.
     
  23. M. S. Furness, X. Zhang, A. Coop, A. E. Jacobson, R. B. Rothman, C. M. Dersch, Q.-X. Zheng, H. Xu, and K. C. Rice: Probes for Narcotic Receptor Mediated Phenomena. 27. Synthesis and Pharmacological Evaluation of Selective Delta-Opioid Receptor Agonists from 4-[(αR)-α-(2S,5R)-4-Substituted-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamides and Their Enantiomers. J. Med. Chem., 2000, 43, 3193-3196.
     
  24. D. C. Broom, L. Guo, A. Coop, S. Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor: BU48: A Novel Buprenorphine Analogue that Exhibits Delta-Opioid Mediated Convulsions but not Delta-Opioid Mediated Antinociception in Mice.J. Pharmacol. Exp. Ther. 2000, 294, 1195-1200.
     
  25. D. Y. Maeda and A. Coop: Studies into the Direct Conversion of the Indolomorphinans into their 4-Phenolic Derivatives. Tetrahedron 2000, 56, 7399-7402.
     
  26. I. Derrick, A. Coop, S. M. Al-Mousawi, S. M. Husbands, and J. W. Lewis: Perchloric Acid Induced Epimerisation of the Thevinones: An Improved Synthesis of 7β-Dihydrothevinones.. Tetrahedron Lett. 2000, 41, 7571-7576.
     
  27. A. Coop, A. E. Jacobson, M. D. Aceto, L. S. Harris, J. R. Traynor, J. H. Woods, and K. C. Rice:N-Cyclohexylethyl-N-noroxymorphindole: A Mu-Opioid Preferring Analog of Naltrindole. Bioorg. Med. Chem. Lett. 2000, 10, 2449-2451.
     
  28. S. McLamore, T. Ullrich, R. B. Rothman, H. Xu, C. M. Dersch, R. Horel, A. Coop, P. Davis, F. Porreca, A. E. Jacobson, and K. C. Rice: The Effect of N-Alkyl and N-Alkenyl Substituents in Noroxymorphindole,17-Substituted-6,7-dehydro-4,5a-epoxy-3,14-dihydroxy-6,7:2’3’-indolomorphinans, on Opioid Receptor Affinity, Selectivity and Efficacy. J. Med. Chem. 2001, 44, 1471-1474.
     
  29. D. Y. Meada, and A. Coop: An Improved Hydrolysis of 7α-Chloro-7β-cyano-6,14-endo-etheno- tetrahydrothebaine to its 7-Oxo Derivative. Heterocycles 2001, 55, 1147-1149.
     
  30. S. M. Huang, T. Bisogno, T. J. Petros, S. Y. Chang, P. A. Zavitsanos, R. E. Zipkin, R. Sivakumar, A. Coop, D. Y. Maeda, L. Petrocellis, S. Burstein, V. DiMarzo, J. M. Walker: Identification and Characterization of an Endogenous Lipoamino Acid that Inhibits Pain: N-Arachidonylglycine (NAGly). J. Biol. Chem. 2001, 276, 42639-42644.
     
  31. A. K. Mehta, N. M. Muschaweck, D. Y. Maeda, A. Coop, and M. K. Ticku: Binding Characteristics of the γ-Hydroxybutyric acid (GHB) Receptor Antagonist [3H]NCS-382 in the Rat Brain. J. Pharmacol. Exp. Ther. 2001, 299, 1148-1153.
     
  32. L.-W. Hsin, X. Tian, E. L. Webster, A. Coop, T. M. Caldwell, A. E. Jacobson, G. P. Chrousos, P. W. Gold, K. E. Habib, A. Ayala, W. C. Eckelman, C. Contoreggi, K. C. Rice: CRHR1 Receptor Binding and Lipophilicity of Pyrrolopyrimidines, Potential Nonpeptide Corticotropin-Releasing Hormone Type 1 Receptor Antagonists. Bioorg. Med. Chem. 2002, 10, 175-183.
     
  33. D. Y. Maeda, W. Williams, W. E. Kim, L. N. Thatcher, W. D. Bowen, and A. Coop: N-Arylalkylpiperidines as High Affinity Sigma-1 and Sigma-2 Receptor Ligands: Phenylpropylamines as Potential Leads for Sigma-2 Agents. Bioorg. Med. Chem. Lett. 2002, 12, 497-500.
     
  34. Cook, C. D.; Aceto, M. D.; Coop, A.; Beardsley, P. M. Effects of the Putative Antagonist, NCS-382, on the Behavioral Pharmacological Actions of Gamma-Hydroxybutyrate (GHB). Psychopharmacology, 2002, 160, 99-106.
     
  35. K. Crawford, A. Coop, and W. D. Bowen: Sigma-2 Receptors Regulate Changes in Sphingolipid Levels in Breast Tumor Cells. Eur. J. Pharmacol. 2002, 443, 207-209.
     
  36. E. L. May, A. Coop, J. H. Woods, M. D. Aceto, E. R. Bowman, L. S. Harris, J. R. Traynor,: N- (Trifluoromethyl)benzyl Substituted N-Normetazocines and N-Norketobemidones. Bioorg. Med. Chem. 2003, 11, 31-31.
     
  37. W. Chen, M. D. Metcalf, A. Coop, J. L. Flippen-Anderson, J. R. Deschamps: 5-Butylthevinone: Stereochemistry of the Diels-Alder Reaction of 5-Butylthebaine with 3-Buten-2-one. Acta Cryst. E, 2003, E59, o114-o116.
     
  38. W. Chen, H. Wu, D. Bernard, M. D. Metcalf, J. R. Deschamps, J. L. Flippen-Anderson, A. D. MacKerell, and A. Coop: Rearrangement of 5-Trimethylsilylthebaine on Treatment with L-Selectride: An Efficient Synthesis of (+)-Bractazonine. J. Org. Chem. 2003, 68, 1929-1932.
     
  39. D. Bernard, A. Coop, and A. D. MacKerell: 2D Conformationally Sampled Pharmacophore: A Ligand Based Pharmacophore to Differentiate Delta Opioid Agonists from Antagonists. J. Am. Chem. Soc., 2003, 125, 3101-3107.
     
  40. A. Foster, H. Wu, W. Chen, W. Williams, W. D. Bowen, R. R. Matsumoto, and A. Coop: 1,4- Dibenzylpiperazines Possess Anticocaine Activity. Bioorg. Med. Chem. Lett., 2003, 13, 749-751.
     
  41. L. R. McMahon, A. Coop, C. P. France, G. Winger, W. L. Woolverton: Evaluation of the Reinforcing and Discriminative Stimulus Effects of 1,4-Butanediol and Gamma-butyrolactone in Rhesus Monkeys. Eur. J. Pharmacol. 2003, 466, 113-120.
     
  42. E. Greiner, M. Spetea, R. Krassnig, F. Schullner, M. D. Aceto, L. S. Harris, J. R. Traynor, J. H. Woods, A. Coop, H. Schmidhammer: Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 18. N- Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships: J. Med. Chem. 2003, 46, 1758-1763.
     
  43. R. M. van Well, H. O. Overkleef, J. H. van Boom, A. Coop, J. B. Wang, H. Wang, G. A. van der Marel, M Overhand: Synthesis of Novel Sugar Amino Acids via a Curtius Rearrangement. Eur. J. Org. Chem. 2003, 1704-1710.
     
  44. L. P. Carter, L. Flores, H. Wu, W. Chen, A.W. Unzeitiz, A. Coop, C.P. France: The Role of GABA-B Receptors in the Discriminative Stimulus Effects of Gamma-Hydroxybutyrate in Rats: Time Course and Antagonism Studies. J. Pharmacol. Exp. Ther. 2003, 305, 668-674.
     
  45. H. Wu, N. Zink, L. P. Carter, A. K. Mehta, R. J. Hernandez, M. Ticku, R. Lamb, C. France, and A. Coop: A Tertiary Alcohol Analog of Gamma-Hydroxybutyric Acid as a Specfic Gamma-Hydroxybutyric Acid Receptor Ligand. J. Pharmacol. Exp. Ther. 2003, 305, 675-679.
     
  46. J. W. Janetka, M. S. Furness, X. Zhang, A. Coop, J. E. Folk, M. V. Mattson, A. E. Jacobson, K. C. Rice: Enantioconvergent Synthesis of (-)-(2R,5S)-1-Allyl-2,5-dimethylpiperazine, an Intermediate to Delta Opioid Ligands. J. Org. Chem. 2003, 68, 3976-3980.
     
  47. R. J. Lamb, J. Munn, N. Duiker, A. Coop, H. Wu, W. Koek, C. P. France: Interactions of γ-Hydroxy Butyrate with Ethanol and NCS-382. Eur. J. Pharmacol. 2003, 470, 157-162.
     
  48. J. Schutz, M. Spetea, M. Koch, M. D. Aceto, L. S. Harris, A. Coop, H. Schmidhammer: Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 20. 14-Phenylpropoxymetopon: An Extremely Powerful Analgesic: J. Med. Chem. 2003, 46, 4182-4187.
     
  49. S. Tolle-Sander, K. A. Lentz, D. Y. Maeda, A. Coop, J. E. Polli: Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. Mol. Pharmaceut. 2004, 1, 40-48.
     
  50. L. P. Carter, L. Flores, H. Wu, W. Chen, C. M. Cruz, R. J. Lamb, W. Koek, A. Coop, C.P. France: Effects of GHB on Schedule-Controlled Responding in Rats: Role of GHB and GABA-B Receptors. J. Pharmacol. Exp. Ther. 2004, 308, 182-188.
     
  51. J. R. Deschamps, A. Coop, D. A. Parrish, K. C. Rice: 7β,14β-Epoxyhydrocodone-6,6-dimethoxy ketal: An Unusual Oxetane Containing Opioid. Acta Cryst. E 2004, E60, o331-o333.
     
  52. W. Koek, L. R. Flores, L. P. Carter, R. J. Lamb, W. Chen, H. Wu, A. Coop, C. P. France: Discriminative Stimulus Effects of g-Hydroxybutyric Acid in Pigeons: Role of Diazepam-Sensitive and -Insensitive GABAA and GABAB Receptors. J. Pharmacol. Exp. Ther. 2004, 308, 904-911.
     
  53. A. T. Macias, R. J. Hernandez, A. K. Metha, A. D. MacKerell, M. K. Ticku, A. Coop:  3-Chloropropanoic Acid (UMB66): A Ligand for the Gamma-Hydroxybutyric Acid Receptor Lacking a 4-Hydroxyl Group. Bioorg. Med. Chem. 2004, 12, 1643-1647.
     
  54. D. Parrish, W. Chen, A. Coop, J. R. Deschamps: 7β-Chloro-6,14-endo-etheno-6,7,8,14-tetrahydrothebaine. Acta Cryst. E 2004, E60, o793-o794.
     
  55. L. P. Carter, A. W. Unzeitig, H. Wu, W. Chen, A. Coop, W. Koek, C. P. France: The Discriminative Stimulus effects of gamma-Hydroxybutyrate and Related Compounds in Rats Discriminating Baclofen or Diazepam: The Role of GABAB and GABAA Receptors. J. Pharmacol. Exp. Ther. 2004, 309, 540-547.
     
  56. R. R. Matsumoto, D. L. Gilmore, B. Pouw, W. D. Bowen, W. Williams, A. Kausar, A. Coop:  Novel Analogs of the Sigma Receptor Ligand BD1008 Attenuate Cocaine-Induced Toxicity in Mice. Eur. J. Pharmacol. 2004, 492, 21-29.
     
  57. M. Spetea, F. Schullner, R. C. Moisa, I. P. Berzetei-Gurske, B. Schraml, C. Dorfler, M. D. Aceto, L. S. Harris, A. Coop, H. Schmidhammer: Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 21. Novel 4-Alkoxy and 14-Phenylpropyl Derivatives of the mu Opioid receptor Antagonist Cyprodime: J. Med. Chem. 2004, 47, 3242-3247.
     
  58. W. Chen, G. D. Strahan, D. A. Parrish, J. R. Deschamps, A. Coop: Studies into the Diels-Alder Reactions of 5-Trimethylsilylthebaine. Tetrahedron Lett. 2005, 46, 131-133.
     
  59. W. E. Fantegrossi, G. Winger, J. H. Woods, W. L. Woolverton, A. Coop,: Reinforcing and Discriminative Stimulus Effects of 1-Benzylpiperazine and Trifluoromethylphenylpiperazine in Rhesus Monkeys. Drug Alcohol Depend. 2005, 77, 161-168.
     
  60. W. Chen, D. A. Parrish, J. R. Deschamps, A. Coop: Functionalization of the 6,14-Bridge of the Orvinols. 1. Preparation and Diels-Alder Reaction of 7-Phenylsilylthebaines. Helv. Chim. Acta 2005, 88, 822-829.
     
  61. H. Wu, D. Bernard, W. Chen, G. D. Strahan, J. R. Deschamps, D. A. Parrish, J. W. Lewis, A. D. MacKerell, A. Coop: Functionalization of the 6,14-Bridge of the Orvinols. 2. Preparation of 18- and 19- Hydroxyl Substituted Thevinols and their Treatment with Benzyl Bromide. J. Org. Chem. 2005, 70, 1907-1910.
     
  62. L. P. Carter, W. Chen, H. Wu, A. K. Mehta, R. J. Hernandez, M. K. Ticku, A. Coop, W. Koek, C. P. France: Comparison of the Behavioral Effects of Gamma-Hydroxybutyric Acid (GHB) and its 4-Methyl-Substituted Analog, Gamma-Hydroxyvaleric Acid (GHV). Drug Alcohol Depend. 2005, 78, 91-99.
     
  63. L. P. Carter, H. Wu, W. Chen, M. M. Matthews, A. K. Mehta, R. J. Hernandez, J. A. Thomson, M. K.Ticku, A. Coop, W. Koek, C. P. France: Novel Gamma-Hydroxybutyric Acid (GHB) Analogs Share Some, But Not All, of the Behavioral Effects of GHB and GABA-B Receptor Agonists. J. Pharmacol. Exp. Ther. 2005, 313, 1314-1323.
     
  64. W. Koek, L. P. Carter, R. J. Lamb, W. Chen, H. Wu, A. Coop, C. P. France: Discriminative Stimulus Effects of γ-Hydroxybutyrate (GHB) in Rats Discriminating GHB from Baclofen and Diazepam. J. Pharmacol. Exp. Ther. 2005, 314, 170-179.
     
  65. W. Chen, H. Wu, R. J. Hernandez, A. K. Mehta, M. K. Ticku, C. P. France, A. Coop: Ethers of 3-Hydroxyphenylacetic Acid as Selective Gamma-Hydroxybutyric Acid Receptor Ligands. Bioorg. Med. Chem. Lett. 2005, 15, 3201-3202.
     
  66. H. Wu, L. N. Thatcher, D. Bernard, D. A. Parrish, J. R. Deschamps, K. C. Rice, A. D. MacKerell, A. Coop: Position of Coordination of the Lithium Ion Determines the Regioselectivity of Demethylations of 3,4- Dimethoxymorphinans with L-Selectride. Org. Lett. 2005, 7, 2531-2534.
     
  67. D. A. Parrish, L. N. Thatcher, H. Wu, A. Coop, J. R. Deschamps: 7-[E]-Benzylidene-14-hydroxy-3,4-dimethoxy-17-methylmorphinan-6-one. Acta Cryst. E. 2005, E61, o2617-o2618.
     
  68. M. Spetea, E. Greiner, M. D. Aceto, L. S. Harris, A. Coop, H. Schmidhammer: Effect of a 6-Cyano Substituent in 14-Oxygenated N-Methylmorphinans on Opioid Receptor Binding and Antinociceptive Potency. J. Med. Chem. 2005, 48, 5052-5055.
     
  69. W. E. Fantegrossi, A. W. Harrington, J. R. Eckler, R. A. Rabin, J. C. Winter, A. Coop, K. C. Rice, J. W. Woods: Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology 2005, 181, 496-503.
     
  70. D. Bernard, A. Coop, A. D. MacKerell: Conformationally Sampled Pharmacophore (CSP) for Peptidic Delta Opioid Ligands. J. Med. Chem. 2005, 48, 7773-7780.
     
  71. C. D. Cook, L. Biddlestone, A. Coop, P. M. Beardsley: Effects of Combining Ethanol with Gamma- Hydroxybutyrate (GHB) on the Discriminative Stimulus, Locomotor and the Motor-Impairing Actions of GHB in Mice. Psychopharmacology 2006, 185, 112-122.
     
  72. W. Koek, W. Chen, S. L. Mercer, A. Coop, C. P. France: Discriminative Stimulus Effects of γ- Hydroxybutyrate: Role of training Dose. J. Pharmacol. Exp. Ther. 2006, 317, 409-417.
     
  73. W. E. Fantegrossi, A. W. Harrington, C. L. Kiessel, J. R. Eckler, R. A. Rabin, J. C. Winter, A. Coop, K. C. Rice, J. H. Woods: Hallucinogen-like Actions of 5-Methoxy-N,N-diisopropyltryptamine in Mice and Rats. Pharmacol. Biochem. Behav. 2006, 83, 122-129.
     
  74. W. Koek, L.P. Carter, H. Wu, A. Coop, C.P. France: Discriminative Stimulus Effects of Flumazenil: Perceptual Masking by Baclofen, and Lack of Substitution with Gamma-Hydroxybutyrate and its Precursors 1,4-Butanediol and Gamma-Butyrolactone. Behav. Pharmacol. 2006, 17, 239-247.
     
  75. C. W. Cunningham, L. N. Thatcher, A. Coop: The Methylation of Non-acidic Alcohols of Alkaloids with TMS-Diazomethane: Conversion of Codeine to Codeine-6-methyl Ether. Heterocycles 2006, 68, 837-840.
     
  76. L. P. Carter, W. Chen, A. Coop, W. Koek, C. P. France: Discriminative Stimulus Effects of GHB and GABAB Agonists are Differentially Attenuated by CGP35348 in rats. Eur. J. Pharmacol. 2006, 538, 85-93.
     
  77. A. Balakrishnan, S. A. Wring, A. Coop, J. E. Polli: Influence of Charge and Steric Bulk in C-24 Region on the Interaction of Bile Acids with Human Apical Sodium Dependent Bile Acid transporter (hASBT). Mol. Pharmaceut. 2006, 3, 282-292.
     
  78. A. Daniels, E. Ayala, B. Pouw, W. Chen, A. Coop, R. R. Matsumot N-[2-(m-Methoxyphenyl)ethyl]-N-ethyl-2-(1-pyrrolidinyl)ethylamine (UMB 116) is a Novel Antagonist for Cocaine-Induced Effects. Eur. J. Pharmacol2006, 542, 61-68.
     
  79. S. L. Mercer, H. E. Hassan, C. W. Cunningham, N. D. Eddington, A. Coop: Opioids and Efflux Transporters. 1. P-Glycoprotein Substrate Activity of N-Substituted Analogs of Merperidine. Bioorg. Med. Chem. Lett. 2007, 17, 1160-1162.
     
  80. R. R. Matsumoto, B. Pouw, A. L. Mack, A. Daniels, A. Coop: Effects of UMB24 and (±)-SM21, putative Sigma-2-preferring Antagonists, on Behavioral, Toxic, and Stimulant Effects of Cocaine in Mice.  Pharmacol. Biochem. Behav. 2007, 86, 86-91.
     
  81. K. Cheng, I. J. Kim, M.-J. Lee, S. A. Adah, T. J. Raymond, E. Bilsky, M. D. Aceto, E. L. May, L. S. Harris, A.Coop, C. M. Dersch, R. B. Rothman, A. E. Jacobson, K. C. Rice: Opioid Ligands with Mixed Properties from Substituted Enantiomeric N-Phenethyl-5-phenylmorphans. Synthesis of a mu-Agonist delta- Antagonist and delta-Inverse Agonists. Org. Biomol. Chem. 2007, 5, 1177-1190.
     
  82. D. Bernard, A. Coop, A. D. MacKerell: Quantitative Conformationally Sampled Pharmacophore (CSP) for Delta Opioid Ligands: Reevaluation of Hydrophobic Moieties Essential for Biological Activity. J. Med. Chem. 2007, 50, 1799-1809.
     
  83. W. Koek, S. L. Mercer, A. Coop: Cataleptic Effects of GHB, its precursor GBL, and GABA-B Agonists: Differential Antagonism by CGP35348. Psychopharmacology 2007, 192, 407-414.
     
  84. A. C. Hiebel, Y. S. Lee, E. Bilsky, D. Giuvelis, J. R. Deschamps, M. D. Aceto, E. L. May, L. S. Harris, A. Coop, C. M. Dersch, R. B. Rothman, A. E. Jacobson, K. C. Rice: Probes for Narcotic receptor Mediated Phenomena.  34. Synthesis and Structure-Activity Relationships of a Potent µ-Agonist δ-Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric 9-Substituted 5-(3-Hydroxyphenyl)-N- phenylethylmorphan Series. J. Med. Chem. 2007, 50, 3765-3776
     
  85. H. Wu, T. A. Smith, H. Huang, J. B. Wang, D. A. Parrish, J. R. Deschamps, A. Coop: Functionalization of   the 6,14-Bridge of the Orvinols. Part 3.  Preparation and Evaluation of 18- and 19-Hydroxyl Substituted Orvinols.  Bioorg. Med. Chem. Lett. 2007, 17, 4829-4831. 
     
  86. H. E. Hassan, A. L. Myers, I. J. Lee, A. Coop, N. Eddington: Oxycodone Induces Overexpression of P- glycoprotein (ABCB1) and Affects Paclitaxel's Tissue Distribution in Sprague Dawley rats. J. Pharm. Sci. 2007, 96, 2494-2506.
     
  87. T. A. Smith, L. N. Thatcher, A. Coop: 3-Hydroxy-4-methoxyindolomorphinans as Delta Opioid Selective Ligands. Bioorg. Med. Chem. Lett. 2007, 17, 5175-5176.
     
  88. J. Wang, A. L. Mack, A. Coop, R. R. Matsumot: Novel Sigma Receptor Agonists Produce Antidepressant -like Effects in Mice. Eur. Neuropsychopharmacol. 2007, 17, 708-716.
     
  89. H. L. Yarosh, E. B. Katz, A. Coop, W. E. Fantegrossi: MDMA-like Behavioral Effects of N-Substituted piperazines in the Mouse. Pharmacol. Biochem. Behav. 2007, 88, 18-27.
  90. M. D. Metcalf, A. Coop: 5’-Halogenated Analogs of Oxymorphindole. Bioorg. Med. Chem. Lett. 2007, 17, 5916-5917.
  91. M.D. Metcalf, M. D. Aceto, L. S. Harris, J. H. Woods, J. R. Traynor, A. Coop, E. L. May: The Influence of Esters and Carboxylic Acids as the N-substituent of Opioids. 1. Benzomorphans. Bioorg. Med. Chem. 2008, 16, 869-873.
  92. C. W. Cunningham, S. L. Mercer, H. E. Hassan, J. R. Traynor, N. D. Eddington, A. Coop: Opioids and Efflux Transporters. Part 2: P-Glycoprotein Substrate Activity of 3- and 6-Substituted Morphine Analogs. J. Med. Chem. 2008, 51, 2316-2320.
  93. S. L. Mercer, R. R. Matsumoto, A. Coop: 4-Cyano-4-phenylpiperidines as Highly Selective Sigma-1 Selective Ligands. Eur. J. Med. Chem. 2008, 43, 1304-1308.
  94. S. L. Mercer, C. W. Cunningham,. N. D. Eddington, A. Coop: Opioids and Efflux Transporters. Part 3: P-Glycoprotein Substrate Activity of 3-Hydroxyl Addition to Meperidine Analogs. Bioorg. Med. Chem. Lett. 2008, 18, 3638-3640.
  95. T. Smith, X. Yang, H. Wu, B. Pouw, R. R. Matsumoto, A. Coop: Trifluoromethoxyl Substituted Phenylethylene Diamines as High Affinity Sigma Receptor Ligands with Potent Anti-cocaine Actions. J. Med. Chem. 2008, 51, 3322-3325.
  96. R. R. Matsumoto, J. Shaikh, L. L. Wilson, S. Vedam, A. Coop: AC927, A Selective Sigma Receptor Antagonist, Attenuates the Locomotor Stimulant and Neurotoxic Effects of Methamphetamine in Mice. Eur. Neuropsychopharmacol. 2008, 18, 871-881.
  97. S. R. Burks, J. Ni, S. Muralidharan, A. Coop, J. P.Y. Kao, G. M. Rosen: Optimization of Labile Esters for Esterase–Assisted Accumulation of Nitroxides into Cells: A Model for In Vivo EPR Imaging. Bioconjugate Chem. 2008, 19, 2068-2071.
  98. T. H. Charpentier, P. T. Wilder, M. A. Liriano, K. M. Varney, E. Pozharski, A. D. MacKerell, A. Coop, E. A. Toth, D. J. Weber: Divalent Metal Ion Complexes of S100B in the Absence and Presence of Pentamidine. J. Mol. Bio. 2008, 382, 56-73.
  99. H. E. Hassan, S.L. Mercer, C.W. Cunningham, A. Coop, N.D. Eddington: Evaluation of the P-Glycoprotein (Abcb1) Affinity Status of a Series of Morphine Analogs: Comparative Study with Meperidine Analogs to Identify Opioids with Minimal P-Glycoprotein Interactions. Int. J. Pharm. 2009, 375, 48-54.
  100. T.H. Charpentier, P.T. Wilder, M.A. Liriano, K.M. Varney, S. Zhong, A. Coop, E. Pozharski, A.D. MacKerell Jr, E.A. Toth, D. J.Weber: Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography. Biochemistry. 2009, 48, 6202-6212.
  101. W. Koek, S. L. Mercer, A. Coop, and C. P. France: Behavioral Effects of GHB, its Precursor GBL, and GABAB Receptor Agonists: Time Course, and Differential Antagonism by the GABAB Receptor Antagonist CGP35348. J. Pharmacol. Exp. Ther. 2009, 330, 876-883.
  102. H. E. Hassan, A.L. Myers, A. Coop, N. D. Eddington: Differential Involvement of P-Glycoprotein (ABCB1) in Permeability, Tissue Distribution, and Antinociceptive Activity of Methadone, Buprenorphine, and Diprenorphine: In Vitro and In Vivo Evaluation. J. Pharm. Sci. 2009, 98, 4928-4940.
  103. H. E. Hassan, A. L. Myers, I. J. Lee, H. Chen, A. Coop, N. D. Eddington: Regulation of Gene Expression in Brain Tissues of Rats Repeatedly Treated by the Highly Abused Opioid Agonist, Oxycodone: Microarray Profiling and Gene Mapping Analysis. Drug Metab. Dispos. 2010, 38, 157-167.
  104. L. C. Cerchietti, A. F. Ghetu, X. Zhu, G. F. Da Silva, S. Zhong, M. Matthews, K. L. Bunting, J. M. Polo, C. Farès, C. H. Arrowsmith, S. N. Yang, M. Garcia, A. Coop, A. D. Mackerell, Jr,, G. G. Privé, A. Melnick:. A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. Cancer Cell, 2010, 17, 315-316.
  105. P. T. Wilder, T. H. Charpentier, M. A. Liriano, K. Gianni, K. M. Varney, E. Pozharski, A. Coop, E. A. Toth, A. D. MacKerell, D. J. Weber: In Vitro Screening and Structural Characterization of Inhibitors of the S100B-p53 Interaction. Int. J,High Throughput Screening 2010, 1, 109-126.
     

Reviews

  1. A. Coop and K. C. Rice: Role of Delta Opioid Receptors in Biological Processes. Drug News and Perspectives. 2000, 13, 481-487.
     
  2. A. Coop and A. D. MacKerell: The Future of Opioid Analgesics. Am. J. Pharm. Educ. 2002, 66, 153-156.
     
  3. S. N. Calderon and A. Coop: SNC 80 and Related Delta Opioid Agonists. Current Pharmaceutical Design 2004, 10, 733-742.
     
  4. D. Bernard, A. Coop, A. D. MacKerell: Computer-Aided Drug Design: Structure-Activity Relationships of Delta Opioid Ligands. Med. Chem. Rev. Online 2005, 2, 277-291.
     
  5. M. D. Metcalf, A. Coop:  Kappa Opioid Antagonists:  Past Successes and Future Prospects.  AAPS J. 2005, 7, Article 71.
     
  6. C. W. Cunningham and A. Coop: Opioid Antagonists. Chemistry Today. 2006, 24 nr 3, 54-57.

Patents

  1. A. Coop and K. C. Rice: Methods of O-Demethylation and N-Deprotection. US 6,395,900, 2002.
     
  2. J. E. Polli, K. A. Lentz, D. Y. Maeda and A. Coop: Bile Acid Containing Prodrugs with Enhanced Bioavailability. Australian Letters Patent Number 2001253226, 2006.
     
  3. A. Coop, M. K. Ticku, C. P. France: Ethers of 3-Hydroxyphenylacetic Acid as Selective Gamma- Hydroxybutyric Acid Receptor Ligands and Therapeutic Uses Thereof. US 7,838,556, 2010.

Book Chapters

  1. A. H. Newman and A. Coop: Medicinal Chemistry: New Chemical Classes and Subtype-Selective Ligands. in “Sigma Receptors: Chemistry, Cell Biology, and Clinical Implications”, Matsumoto, R. R.; Bowen, W. D.; Su, T.-P. (Eds.); Springer-Verlag. 2007 (ISBN: 978-0-387-36512-1).

Monographs

  1. A. Coop and A. E. Jacobson: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXIV. Drug Evaluation Committee of the College on Problems of Drug Dependence (2000), in: Problems of Drug Dependence 2000, ed. L. S. Harris (National Institute on Drug Abuse Research Monograph Series), Washington, DC, 2001, 181, 109-122.
     
  2. A. Coop: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXV. Drug Evaluation Committee of the College on Problems of Drug Dependence (2001). , in: Problems of Drug Dependence 2001, ed. L. S. Harris (National Institute on Drug Abuse Research Monograph Series), Washington, DC, 2002, 182, 124-138.
     
  3. A. Coop: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXVI. Drug Evaluation Committee of the College on Problems of Drug Dependence (2002). , in: Problems of Drug Dependence 2002, ed. W. L. Dewey and L. S. Harris (National Institute on Drug Abuse Research Monograph Series), Washington, DC, 2003, 183, 152-169.
     
  4. A. Coop: Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXVII. Drug Evaluation Committee of the College on Problems of Drug Dependence (2003). , in: Problems of Drug Dependence 2003, ed. W. L. Dewey (National Institute on Drug Abuse Research Monograph Series), Washington, DC, 2004, 184, 135-151.
     
  5. A. Coop: Biological Evaluation of Analgesics, Stimulants, and Depressants. I. An Overview of the Studies Performed by the Drug Evaluation Committee of the College on Problems of Drug Dependence (2004). ed. W. L. Dewey (National Institute on Drug Abuse Research Monograph Series), Washington, DC, 2005, 185, 105-130.
     
  6. A. Coop: Biological Evaluation of Opioids, Stimulants, and Depressants. II. An Overview of the Studies Performed by the Drug Evaluation Committee of the College on Problems of Drug Dependence (2005). ed. W. L. Dewey (National Institute on Drug Abuse Research Monograph Series), Washington, DC, 2006, 186, 145-162.
     
  7. A. Coop: An Overview of the Studies Performed by the Drug Evaluation Committee of the College on Problems of Drug Dependence (2006). ed. W. L. Dewey (National Institute on Drug Abuse Research Monograph Series), Washington, DC, 2007, 187, 100-112.